The objective of this study was to investigate the therapeutic effects of one-shot electroacu-puncture (EA) versus one-shot surface electroacupuncture (SEA) in cervical pain patients. A total of 51 patients were recruited in this randomized control study. Control group (n=13) received medication only. EA group (n=21) received medication plus one-shot of EA.SEA group (n=17) received medication plus one-shot of SEA. Therapeutic effects were measured by Visual Analogue Scale (VAS), body surface score, pain pressure threshold and Quebec Back Pain Disability Scale. The therapeutic effects were shown immediately after the one-shot treatment in both the EA group and the SEA group. In the EA group, the VAS improved 1.99 (p<0.0001), and body surface score was improved 3.52 (p<0.001). In the SEA group, the VAS was improved 1.70 (p<0.0001), and body surface score was improved 1.96 (p<0.005) as well. One week after the treatment, the VAS value in the EA group was improved 2.71 (p<0.0001), whereas the VAS value in the SEA group was improved 2.67 (p<0.0001). The pain surface scores in all three groups had decreased significantly after treatment, but no significant difference was found. Quebec back pain disability scale was improved 10.0 (p<0.005) in the EA group, and was improved 12.4 (p<0.005) in the SEA group 3 days after treatment. One week after treatment, the improved scales were shown with 18.6 (p<0.0005), 22.7 (p<0.005) respectively in the EA group and the SEA group. The improvements were not shown with significant difference between the two groups. Our conclusion is that one-shot treatment of both EA and SEA is effective for pain relief and functional disability improvement in cervical pain patients. Therefore, one-shot SEA treatment is more advised due to the rarity of side effect and the convenience of application.
The objective of this study was to investigate the therapeutic effects of one-shot electroacu-puncture (EA) versus one-shot surface electroacupuncture (SEA) in cervical pain patients. A total of 51 patients were recruited in this randomized control study. Control group (n=13) received medication only. EA group (n=21) received medication plus one-shot of EA.SEA group (n=17) received medication plus one-shot of SEA. Therapeutic effects were measured by Visual Analogue Scale (VAS), body surface score, pain pressure threshold and Quebec Back Pain Disability Scale. The therapeutic effects were shown immediately after the one-shot treatment in both the EA group and the SEA group. In the EA group, the VAS improved 1.99 (p<0.0001), and body surface score was improved 3.52 (p<0.001). In the SEA group, the VAS was improved 1.70 (p<0.0001), and body surface score was improved 1.96 (p<0.005) as well. One week after the treatment, the VAS value in the EA group was improved 2.71 (p<0.0001), whereas the VAS value in the SEA group was improved 2.67 (p<0.0001). The pain surface scores in all three groups had decreased significantly after treatment, but no significant difference was found. Quebec back pain disability scale was improved 10.0 (p<0.005) in the EA group, and was improved 12.4 (p<0.005) in the SEA group 3 days after treatment. One week after treatment, the improved scales were shown with 18.6 (p<0.0005), 22.7 (p<0.005) respectively in the EA group and the SEA group. The improvements were not shown with significant difference between the two groups. Our conclusion is that one-shot treatment of both EA and SEA is effective for pain relief and functional disability improvement in cervical pain patients. Therefore, one-shot SEA treatment is more advised due to the rarity of side effect and the convenience of application.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。